H
Howard A. Burris
Researcher at Sarah Cannon Research Institute
Publications - 593
Citations - 40779
Howard A. Burris is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 80, co-authored 568 publications receiving 34783 citations. Previous affiliations of Howard A. Burris include American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Thomas Powles,Michiel S. van der Heijden,Arjun Vasant Balar,Andrea Necchi,Nancy A. Dawson,Peter H. O'Donnell,Ani Balmanoukian,Yohann Loriot,Sandy Srinivas,Margitta Retz,Petros Grivas,Richard W. Joseph,Matthew D. Galsky,Mark D. Fleming,Daniel P. Petrylak,Jose Luis Perez-Gracia,Howard A. Burris,Daniel Castellano,Christina Canil,Joaquim Bellmunt,Dean F. Bajorin,Dorothee Nickles,Richard Bourgon,Garrett M. Frampton,Na Cui,Sanjeev Mariathasan,Oyewale O. Abidoye,Gregg Fine,Robert Dreicer +30 more
TL;DR: Treatment with atezolizumab resulted in a significantly improved RECIST v1.1 response rate, compared with a historical control overall response rate of 10%, and Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and mutation load to be independently predictive for response to atezolediazepine.
Journal ArticleDOI
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
José Baselga,Mario Campone,Martine Piccart,Howard A. Burris,Hope S. Rugo,Tarek Sahmoud,Shinzaburo Noguchi,Michael Gnant,Kathleen I. Pritchard,Fabienne Lebrun,J. Thaddeus Beck,Yoshinori Ito,Denise A. Yardley,Ines Deleu,Alejandra T. Perez,Thomas Bachelot,L. Vittori,Zhiying Xu,Pabak Mukhopadhyay,David Lebwohl,Gabriel N. Hortobagyi +20 more
TL;DR: Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromat enzyme inhibitors.
Journal ArticleDOI
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles,Joseph Paul Eder,Gregg Fine,Fadi Braiteh,Yohann Loriot,Cristina Cruz,Joaquim Bellmunt,Howard A. Burris,Daniel P. Petrylak,Siew-leng Melinda Teng,Xiaodong Shen,Zachary Boyd,Priti S. Hegde,Daniel S. Chen,Nicholas J. Vogelzang +14 more
TL;DR: It is demonstrated that tumours expressing PD-L1-positive tumour-infiltrating immune cells had particularly high response rates, and patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy.
Journal ArticleDOI
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Kimberly L. Blackwell,Fabrice Andre,Eric P. Winer,Wolfgang Janni,Sunil Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Katarína Petráková,Lowell L. Hart,Cristian Villanueva,A. Chan,Erik Jakobsen,Arnd Nusch,Olga Burdaeva,Eva-Maria Grischke,Emilio Alba,Erik Wist,Norbert Marschner,Anne Favret,Denise A. Yardley,Thomas Bachelot,Ling-Ming Tseng,Sibel Blau,Fengjuan Xuan,Farida Souami,Michelle Miller,C. Germa,Samit Hirawat,Joyce O'Shaughnessy +36 more
TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.
Journal ArticleDOI
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Shirin Khambata-Ford,Christopher R. Garrett,Neal J. Meropol,Mark Basik,Christopher T. Harbison,Shujian Wu,Tai W. Wong,Xin Huang,Chris H. Takimoto,Andrew K. Godwin,Benjamin R. Tan,Smitha S. Krishnamurthi,Howard A. Burris,Elizabeth Poplin,Manuel Hidalgo,José Baselga,Edwin A. Clark,David J. Mauro +17 more
TL;DR: Gene expression profiles showed that patients with tumors that express high levels of the EGFR ligands epiregulin and amphireGulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment.